Associated Papers
Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer.
Corvigno S et al.
Frontiers in Oncology, 2025
40365343 (PubMed )
Supplement: Table11.xlsx › b
Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM.
Ma YS et al.
Molecular Therapy Oncolytics, 2019
31236441 (PubMed )
Supplement: mmc1.pdf
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA et al.
Nature Communications, 2017
29192207 (PubMed )
Supplement: 41467_2017_1864_MOESM3_ESM.xlsx › MCF7-LTEDY537C
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_1_late_met_1
Select a paper to view details